German pharmaceutical giant Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) announced the successful launch of Boehringer Ingelheim’s One Medicine Platform, enabled by the implementation of Veeva Development Cloud. This platform aims to streamline end-to-end processes and enhance information sharing across the organization.
Strategic Partnership
The collaboration between BI and Veeva began in March 2022, with BI leveraging Veeva Development Cloud to drive seamless processes and information sharing. This initiative is part of BI’s Medicine Excellence project, designed to accelerate the development of innovative therapies for currently incurable diseases.
Platform Benefits
The One Medicine Platform allows BI to connect data from various functional departments, optimize trial efficiency, and improve collaboration with research sites. By integrating these technologies, BI aims to speed up the development of new drugs and bring treatments to patients faster.-Fineline Info & Tech
Leave a Reply